COMPASS Pathways Plc - American Depository Shares (CMPS) dividends
CMPS on Nasdaq, Health Care
Sign in to get an email when it declares a dividend.
COMPASS Pathways Plc (CMPS) dividend: key facts
Own COMPASS Pathways Plc (CMPS)? See exactly what it will pay you
Add your shares to a free DiviCompass portfolio to see your next CMPS dividend in your own money, every payment month by month, and an email when it declares. Free for up to 10 holdings, no card needed.
Price history
End-of-day closes on Nasdaq in USD. Dots mark ex-dividend dates.
Dividend history
Declared dividends. Special dividends are marked and excluded from yield and forecasts.
Reported financials
Annual figures from filings, converted to units.
About COMPASS Pathways Plc - American Depository Shares
Compass Pathways, or COMPASS Pathways, is a British pharmaceutical company developing psychedelics as potential medicines. Its main drug candidate, psilocybin (COMP360), has completed phase 3 clinical trials for treatment-resistant depression. The results showed clear benefit to participants as measured on the MADRS depression rating scale. This candidate has received breakthrough therapy status from the U.S. Food and Drug Administration (FDA). It is the most advanced psychedelic drug candidate in development besides Lykos Therapeutics's midomafetamine (MDMA). Compass Pathways is the largest company in the psychedelic medicine industry and, in 2020, was the first psychedelic medicine company to be listed on the NASDAQ. It has faced criticism for patenting psychedelic drugs and even certain psilocybin mushroom species.
From Wikipedia, CC BY-SA 4.0.
Next 12 months
No dividends expected from the data available.
Estimate confidence: None
Company news
- Compass Pathways to Participate in Jefferies Global Healthcare Conference on November 18th and 19th11 Nov 2026 · Business Wire
LONDON & JERSEY CITY, N.J.--(BUSINESS WIRE)---- $CMPS #Biotech--Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to unlocking urgently needed new treatment options in mental heal...
- Compass Pathways submitts NDA to FDA for COMP360 psilocybin9 Nov 2026 · TheFly
Compass Pathways (CMPS) announced the Company completed its submission of a New Drug Application, or NDA, to the FDA for COMP360 psilocybin, its investigational synthetic, proprietary formulation of p...
- Compass Pathways Completes COMP360 Psilocybin New Drug Application to U.S. FDA for Treatment-Resistant Depression9 Nov 2026 · Business Wire
LONDON & JERSEY CITY, N.J.--(BUSINESS WIRE)---- $CMPS #Biotech--Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to unlocking urgently needed new treatment options in mental heal...
- Compass Pathways Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)6 Nov 2026 · Business Wire
LONDON & JERSEY CITY, N.J.--(BUSINESS WIRE)---- $CMPS #Biotech--Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to unlocking urgently needed new treatment options in mental heal...
- Psychedelic: Compass Pathways beats Q3 loss estimate5 Nov 2026 · TheFly
In this weekâs âPsychedelic,â The Flyâs recurring series focused on psychedelic stock news, The Fly looks back on earnings, an extraction completion and analyst views. COMPASS REPORTS EARNINGS: On Tue...
- Compass Pathways to Participate in Stifel 2026 Healthcare Conference on November 11th4 Nov 2026 · Business Wire
LONDON & JERSEY CITY, N.J.--(BUSINESS WIRE)---- $CMPS #Biotech--Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to unlocking urgently needed new treatment options in mental heal...
- Compass Pathways sees current cash position sufficient into 20283 Nov 2026 · TheFly
06:44 EST Compass Pathways (CMPS) sees current cash position sufficient into 2028
- Compass Pathways reports Q3 EPS (31c), consensus (33c)3 Nov 2026 · TheFly
Cash and cash equivalents were $444.0M as of September 30, 2026, vs. $149.6M as of December 31, 2025. âCompass is leading one of the most important advances in mental healthâ¦
Insufficient verified data for a financial-health score
Dividend data and price last updated 18 Nov 2026.